Compare · LUNG vs SYK
LUNG vs SYK
Side-by-side comparison of Pulmonx Corporation (LUNG) and Stryker Corporation (SYK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LUNG and SYK operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- SYK is the larger of the two at $112.48B, about 1415.6x LUNG ($79.5M).
- Over the past year, LUNG is up 15.7% and SYK is down 21.3% - LUNG leads by 37.0 points.
- SYK has been more active in the news (8 items in the past 4 weeks vs 1 for LUNG).
- SYK has more recent analyst coverage (25 ratings vs 17 for LUNG).
- Company
- Pulmonx Corporation
- Stryker Corporation
- Price
- -
- -
- Market cap
- $79.5M
- $112.48B
- 1M return
- -11.06%
- +5.16%
- 1Y return
- +15.69%
- -21.34%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2020
- News (4w)
- 1
- 8
- Recent ratings
- 17
- 25
Pulmonx Corporation
Pulmonx Corporation, a medical technology company, designs, develops, manufactures, and markets minimally invasive medical devices for the diagnosis and treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also provides StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.
Stryker Corporation
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. The Neurotechnology and Spine segment provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.
Latest LUNG
- Pulmonx to Report Third Quarter 2026 Financial Results on October 27, 2026
- SEC Form 4 filed by Pulmonx Corporation
- Chief Science & Techn. Officer Radhakrishnan Srikanth sold $32,194 worth of shares (14,245 units at $2.26), decreasing direct ownership by 4% to 316,994 units (SEC Form 4) (tax withholding)
- General Counsel Lehman David Aaron sold $32,395 worth of shares (14,334 units at $2.26), decreasing direct ownership by 4% to 361,827 units (SEC Form 4) (tax liability)
- Chief Commercial Officer Rose Geoffrey Beran sold $17,807 worth of shares (7,879 units at $2.26), decreasing direct ownership by 2% to 449,832 units (SEC Form 4) (tax withholding)
- Pulmonx Corporation Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Pulmonx to Participate in Upcoming Investor Conferences
- Amendment: SEC Form SCHEDULE 13G/A filed by Pulmonx Corporation
- SEC Form 10-Q filed by Pulmonx Corporation
- Pulmonx Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
Latest SYK
- Stryker launches Sonopet® 3, delivering greater power and precision in ultrasonic tissue removal
- Stryker and CMR Surgical announce strategic alliance to advance robotic-assisted surgery
- Barclays initiated coverage on Stryker with a new price target
- SEC Form 8-K filed by Stryker Corporation
- Stryker announces leadership succession
- Stryker to announce third quarter 2026 financial results
- VP, Chief Financial Officer Wells Preston Wendell disposed of 109 shares, decreasing direct ownership by 3% to 3,661 units (SEC Form 4)
- VP, Chief Financial Officer Wells Preston Wendell disposed of 2,739 shares, decreasing direct ownership by 42% to 3,770 units (SEC Form 4)
- Stryker showcases Foot & Ankle innovation at AOFAS 2026 with Prophecy® Surgical Planning for Incompass™ and Hoffmann® LRF smartHEX™
- New insider Baculik Emily Kay claimed ownership of 1,554 shares (SEC Form 3)